title: Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation.
authors.forename: Kun-Ming
authors.initials: KM
authors.lastname: Chan
authors.forename: Ching-Sung
authors.initials: CS
authors.lastname: Lee
authors.forename: Ting-Jung
authors.initials: TJ
authors.lastname: Wu
authors.forename: Chen-Fang
authors.initials: CF
authors.lastname: Lee
authors.forename: Tse-Ching
authors.initials: TC
authors.lastname: Chen
authors.forename: Wei-Chen
authors.initials: WC
authors.lastname: Lee
mesh_terms: D000368:Aged; D001788:Blood Grouping and Crossmatching; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D056724:Immunity, Humoral / Q000276:immunology*; D015994:Incidence; D007223:Infant; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib